Please review the QC test results indicated by 
icon below as well as clone information before placing your order.
提供案内 (日本国内) 
[open/close]
Please review the QC test results indicated by icon below as well as clone information before placing your order.
icon below as well as clone information before placing your order.
pCMFlag_hsMAFB (#RDB06264)
Expression vector of human MAFB.
| Alternative name | SET-0059_32 |
|---|---|
| Clone info. | Expression vector of human MAFB. Expression was confirmed by Western blotting with anti-FLAG antibody. |
| Comment | PCR cloning, forward primer: gccgcggagctgagcatggggccagag; reverse primer: tcacagaaagaactcgggagaggaggggct. |
| Vector backbone | pCMV_S-FLAG (RDB05956) (Plasmid) |
| Size of vector backbone | 5.5 kb |
| Selectable markers | Amp^r (E. coli), Neo^r (mammalian cell) |
| Growth conditions | 37C, LB+Amp |
| Gene/insert name | Human KRML; MAFB cDNA |
| Depositor|Developer | DNA Bank, | |
| Remarks, protocol and/or map (pdf) | RDB06264.pdf |
|---|
Distribution information
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
| Ordering forms | Order form [Credit Card Payment  ] [Bank Transfer Payment] [Example of order form ]MTA, for use for not-for-profit academic purpose [Word ] [Example of MTA ]MTA, for use for for-profit purpose [Word ]Please visit Information of Request for Distribution.[link] |
|---|---|
| Terms and conditions for distribution | The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL in any publication. Additional terms and conditions: Regrding pRc/CMV: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
[open/close]| 必要書類 | 提供依頼書 [依頼書の記入例 ]提供同意書 (MTA, 非営利学術目的用)[Word ] [MTAの記入例 ]提供同意書 (MTA, 営利目的用)[Word ]手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
|---|---|
| MTAに書く使用条件 | 発表に際し、理研BRCから入手したことを明記すること。 付加的使用条件： pRc/CMVについて: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
| Catalog # | Resource name | Shipping form | Fee |
|---|---|---|---|
| RDB06264 | pCMFlag_hsMAFB | DNA solution |
JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge |
icon below as well as clone information before placing your order.How to cite this biological resource
Materials & Methods section:
| The pCMFlag_hsMAFB was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB06264). |
Reference section:
Further references such as user reports and related articles (go to bottom)
QC test results
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
| Test sheet | RDB19601_B2Dkp1-1.pdf |
|---|
Nucleotide sequence of a portion of this resource (if available).
|
Primer: CMV_Forward (Pr0016) Region: CMV pro,FLAG,insert 5' Sequence file: RDB19601_B2Dka.seq
|
|---|
|
>06264_19601_B2Dk_CMV_Forward_F01_06_ABI08.ab1 1 NNNNNNNNNN NNNNNTNNNN GCNNATGGGC GGTAGGCGTG TACGGTGGGA GGTCTATATA 61 AGCAGAGCTC TCTGGCTAAC TAGAGAACCC ACTGCTTACT GGCTTATCGA AATTAATACG 121 ACTCACTATA GGGAGACCCA AGCTGAATTC ACCATGGACT ACAAGGACGA TGACGATAAG 181 GCGGCCGCCG CGGAGCTGAG CATGGGGCCA GAGCTGCCCA CCAGCCCGCT GGCCATGGAG 241 TATGTCAACG ACTTCGACCT GCTCAAGTTC GACGTGAAGA AGGAGCCACT GGGGCGCGCG 301 GAGCGTCCGG GCAGGCCCTG CACACGCCTG CAGCCAGCCG GCTCGGTGTC CTCCACACCG 361 CTCAGCACTC CGTGTAGCTC CGTGCCCTCG TCGCCCAGCT TCAGCCCGAC CGAACAGAAG 421 ACACACCTCG AGGATCTGTA CTGGATGGCG AGCAACTACC AGCAGATGAA CCCCGAGGCG 481 CTCAACCTGA CGCCCGAGGA CGCGGTGGAA GCGCTCATCG GCTCGCACCC AGTGCCACAG 541 CCGCTGCAAA GCTTCGACAG CTTTCGCGGC GCTCACCACC ACCACCATCA CCACCACCCT 601 CACCCGCACC ACGCGTACCC GGGCGCCGGC GTGGCCNACG ACGANCTGGG CCNGCACGCT 661 CNCCCGCACC ATCNCCATCA TCNNNNAGCG TCNCCNCCGN NNTNNNGCNN NNCTANCCCN 721 GNNNNNNNNN CNNNCNNNNN NNNNN // |
|
Primer: bGH_rev3 (Pr0885) Region: bGH pA,insert 3' Sequence file: RDB19601_B2Dkb.seq
|
|
>06264_19601_B2Dk_bGH_rev3_G01_07_ABI08.ab1 1 NNNNNNNNNN NNNNNNNGGG GNNGGGCNNA CAACAGATGG CTGGCAACTA GAAGGCACAG 61 TCGAGGCTGA TCAGCGAGCT CTAGCATTTA GGTGACACTA TAGAATAGGG CCCTCTAGAT 121 GCATGCTCGA GCGGCCTCAC AGAAAGAACT CGGGAGAGGA GGGGCTGTCG CTGGTGGAGC 181 CCGCCTCCCT GAAGCCGGAG TTGGCGAGTT TCTCGCACTT GACCTTGTAG GCGTCTCTCT 241 CGCGGGCCAG CCGGGACACC TCCTGCTTAA GCTGCTCCAC CTGCTGAATG AGCTGCGTCT 301 TCTCATTCTC CAGGTGGTGC TTCTGCTGGA CGCGTTTATA CCTGCAAGAC TGGGCGTAGC 361 CCCGGTTCTT CAGGGTCCGC CGCTTCTGCT TCAGGCGGAT CACCTCGTCC TTGGTGAAGC 421 CCCGCAGGTG GCGGTTCAGC TCGCGCACGG ACATGGACAC GAGCTGGTCG TCGGAGAAGC 481 GGTCCTCCAC GCTGCCGTTG CCGCCCGCCG CCGTCGCCGA GGCCGTCGCG TGCGGCCCGG 541 GCCCGGGGTG GCTAGTGGGC AGCTGTTGCG CCGGGCTAGC GGCGCTGGAC GGCGGCGGCG 601 ACGCTTGGTG ANGATGGTGA TGGTGCGGGT GAGCGTGCGG GCCCNGCTCG TCNTGGGCCA 661 CGCCNGCGCC NNGGNACNCN NNGNGCGGGT GANGGTGGTG NNGATGGNNN NNNNNNN // |
|
Primer: SV40pro_ori_F (Pr0731) Region: SV40 pro_ori,NeoR Sequence file: RDB19601_B2Dkc.seq
|
|
>06264_19601_B2Dk_SV40pro_ori_F_H01_08_ABI08.ab1 1 NNNNNNNNNN NNNGCCGCCT CNGCCTCTGA NCTATTCCNG AAGTAGTGAG GAGGCTTTTT 61 TGGAGGCCTA GGCTTTTGCA AAAAGCTCCC GGGAGCTTGG ATATCCATTT TCGGATCTGA 121 TCAAGAGACA GGATGAGGAT CGTTTCGCAT GATTGAACAA GATGGATTGC ACGCAGGTTC 181 TCCGGCCGCT TGGGTGGAGA GGCTATTCGG CTATGACTGG GCACAACAGA CAATCGGCTG 241 CTCTGATGCC GCCGTGTTCC GGCTGTCAGC GCAGGGGCGC CCGGTTCTTT TTGTCAAGAC 301 CGACCTGTCC GGTGCCCTGA ATGAACTGCA GGACGAGGCA GCGCGGCTAT CGTGGCTGGC 361 CACGACGGGC GTTCCTTGCG CAGCTGTGCT CGACGTTGTC ACTGAAGCGG GAAGGGACTG 421 GCTGCTATTG GGCGAAGTGC CGGGGCAGGA TCTCCTGTCA TCTCACCTTG CTCCTGCCGA 481 GAAAGTATCC ATCATGGCTG ATGCAATGCG GCGGCTGCAT ACGCTTGATC CGGCTACCTG 541 CCCATTCGAC CACCAAGCGA AACATCGCAT CGAGCGAGCA CGTACTCGGA TGGAAGCCGG 601 TCTTGTCGAT CAGGANGANC TGGACNAAGA GCATCANGGG CTCGCGCCAG CCGAACTGNT 661 CGCCAGGCTC NNNGCGCGCA NGNCCNANNG CNANGNNCTC NNCNNGNNCC NNGGNNANGC 721 CNGCNNNNCN ANNNNNCNNG GNNNNAANNN NNNNNNN // |
Please visit 
Sequencing and PCR primers for primer information.
References
Original, user report and related articles
Resource search
Link
Other resources in our bankExternal Database
Human KRML; MAFB
Reference sequence
Tips
Featured content
